GRCE · Insider Trading
Grace Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by GRCE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-26 | Opaleye Management Inc. | 10%+ Owner | Buy | +87,801 | +$158.60K |
| 2026-10-21 | Opaleye Management Inc. | 10%+ Owner | Buy | +4,256 | +$8.00K |
| 2026-10-16 | Opaleye Management Inc. | 10%+ Owner | Buy | +71,065 | +$136.18K |
| 2026-10-13 | Opaleye Management Inc. | 10%+ Owner | Buy | +14,632 | +$29.68K |
| 2026-10-05 | Opaleye Management Inc. | 10%+ Owner | Buy | +60,490 | +$123.82K |
| 2026-10-01 | Opaleye Management Inc. | 10%+ Owner | Buy | +15,089 | +$31.69K |
| 2026-10-01 | Opaleye Management Inc. | 10%+ Owner | Buy | +7,849 | +$16.40K |
| 2026-09-23 | Opaleye Management Inc. | 10%+ Owner | Buy | +15,089 | +$31.69K |
| 2026-09-21 | Vimal Kavuru | Director | A | +12,200 deriv. | — |
| 2026-09-21 | George Kottayil | Director | A | +12,200 deriv. | — |
| 2026-09-21 | A Brian Davis | Director | A | — | — |
| 2026-09-21 | Edward Neugeboren | Director | A | +12,200 deriv. | — |
| 2026-09-10 | Prashant Kohli | Chief Executive Officer | Buy | +100,000 | +$214.00K |
| 2026-09-10 | Opaleye Management Inc. | 10%+ Owner | Buy | +15,229 | +$31.90K |
| 2026-09-01 | Amresh Kumar | VP Program Management | A | +35,760 deriv. | — |
| 2026-09-01 | Prashant Kohli | Chief Executive Officer | A | +267,160 deriv. | — |
| 2026-09-01 | R. Loch Macdonald | Chief Medical Officer | A | +54,690 deriv. | — |
| 2026-09-01 | Robert J DelAversano | Principal Financial Officer | A | +33,660 deriv. | — |
| 2026-08-19 | Opaleye Management Inc. | 10%+ Owner | Buy | +11,608 | +$24.21K |
| 2026-01-12 | Vimal Kavuru | Director | A | +10,000 deriv. | — |
| 2026-01-12 | A Brian Davis | Director | A | +10,000 deriv. | — |
| 2026-01-12 | George Kottayil | Director | A | +10,000 deriv. | — |
| 2026-01-12 | Edward Neugeboren | Director | A | +10,000 deriv. | — |
| 2025-05-13 | Edward Neugeboren | Director | A | +10,000 deriv. | — |
| 2025-05-13 | George Kottayil | Director | A | +10,000 deriv. | — |
| 2025-05-13 | A Brian Davis | Director | A | +10,000 deriv. | — |
| 2025-05-13 | Vimal Kavuru | Director | A | +10,000 deriv. | — |
| 2025-04-16 | Robert J DelAversano | Principal Financial Officer | A | +20,130 deriv. | — |
| 2025-04-16 | Carrie D'Andrea | VP Clinical Operations | A | +30,000 deriv. | — |
| 2025-04-16 | R. Loch Macdonald | Chief Medical Officer | A | +40,000 deriv. | — |
| 2025-04-16 | Amresh Kumar | VP Program Management | A | +30,000 deriv. | — |
| 2025-04-16 | Prashant Kohli | Chief Executive Officer | A | +225,400 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Opaleye Management Inc. | 10%+ Owner | 2,948,610 | $5.34M |
| Prashant Kohli | Chief Executive Officer | 121,357 | $219.66K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GRCE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.